Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors
Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China
Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July
